Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Motoko Ida; Akito Nishida; Hiraku Akiho; Yoshihiro Nakashima; Kei Matsueda; Shin Fukudo

doi:10.1186/s13030-017-0093-9

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Biopsychosoc Med. 2017 Mar 16:11:8. doi: 10.1186/s13030-017-0093-9. eCollection 2017.

Authors

Motoko Ida¹, Akito Nishida², Hiraku Akiho³, Yoshihiro Nakashima⁴, Kei Matsueda⁵, Shin Fukudo⁶

Affiliations

¹ Japan-Asia Planning & Administration, Medical & Development, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411 Japan.
² Development Project Management, Astellas Pharma Inc., Tokyo, Japan.
³ Japan-Asia Clinical Development 2, Development, Astellas Pharma Inc., Tokyo, Japan.
⁴ Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
⁵ Sakura Life Clinic, Tokyo, Japan.
⁶ Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Abstract

Background: Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS) symptoms. However, it was deemed important to assess "clinically meaningful improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" in addition to global assessment to show how ramosetron is effective for individual IBS symptoms. This is a pilot study to explore clinical endpoints focusing on the chief complaint of patients with IBS with diarrhea (IBS-D).

Methods: The same database was used in a previously reported post-marketing phase IV, randomized placebo-controlled pilot trial in male patients with IBS-D. The hypothesis is completely different from that of the other study. Patients with IBS-D diagnosed according to Rome III criteria were given either 5 μg of ramosetron (n = 47) or placebo (n = 51) once daily for 12 weeks after a one-week baseline period. To explore and examine endpoints that allow evaluation of "clinically meaningful improvements focusing on the patient's chief complaint," the chief complaint and its relief by this study drug were assessed in this exploratory study.

Results: Rates of patients with abdominal pain/discomfort, stool form and stool frequency which patients had as a chief complaint before administration were 34.0, 19.1 and 25.5%, respectively, in the ramosetron 5 μg group and 42.0, 18.0, and 20.0% in the placebo group. Responder rates for improvement in symptoms of the chief complaint that patients had before administration were 53.2% in the ramosetron 5 μg group and 42.0% in the placebo group at the last point. The greatest symptomatic improvement in the chief complaint in the ramosetron 5 μg group compared to the placebo group was shown with respect to stool consistency. Bristol Stool Form Scale (BSFS) scores were significantly lower in the ramosetron group than in the placebo group (4.36 ± 1.195 vs 4.85 ± 0.890 at the last point, P = 0.027) throughout the treatment period, except at week 6.

Conclusions: Ramosetron acted most effectively on stool consistency. Improvement in stool consistency is considered to be a clinically meaningful endpoint in showing how ramosetron was effective for individual IBS symptoms. (Clinicaltrials.gov ID: NCT00918411. Registered 9 June 2009).

Keywords: 5-hydroxytryptamine (5-HT); Abdominal discomfort; Abdominal pain; Global improvement; Stool consistency.

Associated data

ClinicalTrials.gov/NCT00918411